Na Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Na Li has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed I. Elsaid
Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH
4 shared publications - Vinod K. Rustgi
Division of Gastroenterology and Hepatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
3 shared publications - Electra D. Paskett
The Ohio State University
2 shared publications - Khalid Mumtaz
Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio
2 shared publications Bilal Hameed
Department of Medicine, University of California, San Francisco, California
1 shared publicationCarlos Romero-Marrero
South Florida Transplant Center, Broward Health Medical Center, Fort Lauderdale, Florida
1 shared publication
Latest Publications
- Open Access
- 5 May 2026
- Published by Elsevier in Gastro Hep Advances
- Vol. 5 (7) , 100992
Nonlinear Association Between Metabolic Syndrome Severity and Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease
- 5 May 2026
- Published by Elsevier in Gastro Hep Advances
- Vol. 5 (7) , 100992
Open AccessNonlinear Association Between Metabolic Syndrome Severity and Advanced Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease
- Open Access
- 17 March 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71721
Impacts of Neighborhood Persistent Poverty and Socioeconomic Status on Hepatocellular Carcinoma Outcomes: A Large Population‐Based Cohort Study
Background: Hepatocellular carcinoma (HCC) survival in the United States varies sharply by neighborhood disadvantage. Aim: To determine whether residence in persistently impoverished or low‐SES census tracts is independently associated with lower all‐cause and HCC‐specific survival. Methods: We identified 51,323 adults with HCC using a population‐based retrospective cohort from the Surveillance, Epidemiology, and End Results Research Plus Specialized Database (2006–2020). Two census tract‐level socioeconomic exposures were defined: persistent poverty (≥ 20% living below the poverty line for approximately 30 years) and low SES (Yost Index first quintile). Overlap Propensity Score Weighting, combined with marginal structural models, estimated the 1‐, 5‐, 10‐, and 15‐year risks of all‐cause and HCC‐specific mortality. Results: The median follow‐up was 16 months, 6058 (11.8%) lived in persistently impoverished tracts, and 9863 (19.5%) lived in low‐SES tracts. After weighting, residents of persistently impoverished areas had a 1‐year all‐cause mortality risk of 46.0% vs. 40.3% (RD, 5.6%; 95% CI, 4.4% to 6.9%; RR, 1.14; 95% CI, 1.11 to 1.17) and an HCC‐specific mortality risk of 33.3% vs. 28.6% (RD, 4.8%; 95% CI, 3.2% to 6.3%; RR, 1.17; 95% CI, 1.11 to 1.22). Living in low‐SES tracts raised 1‐year all‐cause mortality risk to 32.5% vs. 30.1% (RD, 4.8%; 95% CI, 3.6% to 6.0%; RR, 1.12; 95% CI, 1.09 to 1.15) and HCC‐specific mortality risk to 32.5% vs. 30.1% (RD, 2.5%; 95% CI, 1.4% to 3.5%; RR, 1.08; 95% CI, 1.05 to 1.12). Conclusions: Both persistent neighborhood poverty and contemporary low SES independently contribute to significant increases in mortality risk after HCC diagnosis.
- 17 March 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71721
Open AccessImpacts of Neighborhood Persistent Poverty and Socioeconomic Status on Hepatocellular Carcinoma Outcomes: A Large Population‐Based Cohort Study
Background: Hepatocellular carcinoma (HCC) survival in the United States varies sharply by neighborhood disadvantage. Aim: To determine whether residence in persistently impoverished or low‐SES census tracts is independently associated with lower all‐cause and HCC‐specific survival. Methods: We identified 51,323 adults with HCC using a population‐based retrospective cohort from the Surveillance, Epidemiology, and End Results Research Plus Specialized Database (2006–2020). Two census tract‐level socioeconomic exposures were defined: persistent poverty (≥ 20% living below the poverty line for approximately 30 years) and low SES (Yost Index first quintile). Overlap Propensity Score Weighting, combined with marginal structural models, estimated the 1‐, 5‐, 10‐, and 15‐year risks of all‐cause and HCC‐specific mortality. Results: The median follow‐up was 16 months, 6058 (11.8%) lived in persistently impoverished tracts, and 9863 (19.5%) lived in low‐SES tracts. After weighting, residents of persistently impoverished areas had a 1‐year all‐cause mortality risk of 46.0% vs. 40.3% (RD, 5.6%; 95% CI, 4.4% to 6.9%; RR, 1.14; 95% CI, 1.11 to 1.17) and an HCC‐specific mortality risk of 33.3% vs. 28.6% (RD, 4.8%; 95% CI, 3.2% to 6.3%; RR, 1.17; 95% CI, 1.11 to 1.22). Living in low‐SES tracts raised 1‐year all‐cause mortality risk to 32.5% vs. 30.1% (RD, 4.8%; 95% CI, 3.6% to 6.0%; RR, 1.12; 95% CI, 1.09 to 1.15) and HCC‐specific mortality risk to 32.5% vs. 30.1% (RD, 2.5%; 95% CI, 1.4% to 3.5%; RR, 1.08; 95% CI, 1.05 to 1.12). Conclusions: Both persistent neighborhood poverty and contemporary low SES independently contribute to significant increases in mortality risk after HCC diagnosis.
- Open Access
- 27 March 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (9) , 1096-1110
Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
Summary: Background/Aims: We examined the effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) initiation on long‐term Adverse Liver Outcomes (ALO) in patients with Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) cirrhosis and type 2 diabetes using real‐world data from the MarketScan database.Methods: We conducted a retrospective cohort study of patients with MASLD cirrhosis and type 2 diabetes between 2012 and 2020. Cox proportional hazard models examine the association between GLP‐1RAs initiation, modelled as time‐dependent, and the risk of ALO, a composite endpoint defined by the first occurrence of hepatic decompensation(s), portal hypertension, hepatocellular carcinoma (HCC) or liver transplantation (LT). We used Overlap Propensity Score Weighting (OPSW) to account for confounding. The study included 459 GLP‐1RAs and 4837 non‐GLP‐1RAs patients.Results: The non‐GLP‐1RAs patients presented with 1411 (29%) ALO over 7431.7 person years, while GLP‐1RAs patients had 32 (7%) ALO over 586.6 person years – risk rate difference 13.5 (95% CI: 11.4–15.7) per 100 person‐years. The OPSW‐adjusted risk of ALO was reduced by 36% (hazard ratio [HR]: 0.64; 95% CI: 0.54–0.76) in patients with vs. without GLP‐1RAs initiation. GLP‐1RAs initiation was associated with significant reductions in the adjusted risk of hepatic decompensation (HR: 0.74; 95% CI: 0.61–0.88), portal hypertension (HR: 0.73; 95% CI: 0.60–0.88), HCC (HR: 0.37; 95% CI: 0.20–0.63) and LT (HR: 0.24; 95% CI: 0.12–0.43).Conclusion: The use of GLP‐1RAs was associated with significant risk reductions in long‐term adverse liver outcomes, including hepatic decompensation, portal hypertension, HCC and LT, in MASLD cirrhosis patients with type 2 diabetes.
- 27 March 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (9) , 1096-1110
Open AccessImpacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
Summary: Background/Aims: We examined the effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) initiation on long‐term Adverse Liver Outcomes (ALO) in patients with Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) cirrhosis and type 2 diabetes using real‐world data from the MarketScan database.Methods: We conducted a retrospective cohort study of patients with MASLD cirrhosis and type 2 diabetes between 2012 and 2020. Cox proportional hazard models examine the association between GLP‐1RAs initiation, modelled as time‐dependent, and the risk of ALO, a composite endpoint defined by the first occurrence of hepatic decompensation(s), portal hypertension, hepatocellular carcinoma (HCC) or liver transplantation (LT). We used Overlap Propensity Score Weighting (OPSW) to account for confounding. The study included 459 GLP‐1RAs and 4837 non‐GLP‐1RAs patients.Results: The non‐GLP‐1RAs patients presented with 1411 (29%) ALO over 7431.7 person years, while GLP‐1RAs patients had 32 (7%) ALO over 586.6 person years – risk rate difference 13.5 (95% CI: 11.4–15.7) per 100 person‐years. The OPSW‐adjusted risk of ALO was reduced by 36% (hazard ratio [HR]: 0.64; 95% CI: 0.54–0.76) in patients with vs. without GLP‐1RAs initiation. GLP‐1RAs initiation was associated with significant reductions in the adjusted risk of hepatic decompensation (HR: 0.74; 95% CI: 0.61–0.88), portal hypertension (HR: 0.73; 95% CI: 0.60–0.88), HCC (HR: 0.37; 95% CI: 0.20–0.63) and LT (HR: 0.24; 95% CI: 0.12–0.43).Conclusion: The use of GLP‐1RAs was associated with significant risk reductions in long‐term adverse liver outcomes, including hepatic decompensation, portal hypertension, HCC and LT, in MASLD cirrhosis patients with type 2 diabetes.
- Open Access
- 8 April 2022
- Published by Elsevier in Gastro Hep Advances
- Vol. 1 (3) , 445-456
Metabolic Syndrome Severity Predicts Mortality in Nonalcoholic Fatty Liver Disease
- 8 April 2022
- Published by Elsevier in Gastro Hep Advances
- Vol. 1 (3) , 445-456
Open AccessMetabolic Syndrome Severity Predicts Mortality in Nonalcoholic Fatty Liver Disease
- 1 March 2022
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 18 (3) , 314-325
ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis
- 1 March 2022
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 18 (3) , 314-325
ASMBS Position Statement on the Impact of Metabolic and Bariatric Surgery on Nonalcoholic Steatohepatitis